» Articles » PMID: 31492812

RNA Editing Alterations Define Manifestation of Prion Diseases

Abstract

Prion diseases are fatal neurodegenerative disorders caused by misfolding of the normal prion protein into an infectious cellular pathogen. Clinically characterized by rapidly progressive dementia and accounting for 85% of human prion disease cases, sporadic Creutzfeldt-Jakob disease (sCJD) is the prevalent human prion disease. Although sCJD neuropathological hallmarks are well-known, associated molecular alterations are elusive due to rapid progression and absence of preclinical stages. To investigate transcriptome alterations during disease progression, we utilized tg340-129MM mice infected with postmortem material from sCJD patients of the most susceptible genotype (MM1 subtype), a sCJD model that faithfully recapitulates the molecular and pathological alterations of the human disease. Here we report that transcriptomic analyses from brain cortex in the context of disease progression, reveal epitranscriptomic alterations (specifically altered RNA edited pathway profiles, eg., ER stress, lysosome) that are characteristic and possibly protective mainly for preclinical and clinical disease stages. Our results implicate regulatory epitranscriptomic mechanisms in prion disease neuropathogenesis, whereby RNA-editing targets in a humanized sCJD mouse model were confirmed in pathological human autopsy material.

Citing Articles

Single-cell transcriptomics unveils molecular signatures of neuronal vulnerability in a mouse model of prion disease that overlap with Alzheimer's disease.

Slota J, Lamoureux L, Frost K, Sajesh B, Booth S Nat Commun. 2024; 15(1):10174.

PMID: 39580485 PMC: 11585576. DOI: 10.1038/s41467-024-54579-2.


New preclinical biomarkers for prion diseases in the cerebrospinal fluid proteome revealed by mass spectrometry.

Perez-Lazaro S, Barrio T, Bravo S, Sevilla E, Otero A, Chantada-Vazquez M Vet Q. 2024; 44(1):1-15.

PMID: 39520708 PMC: 11552261. DOI: 10.1080/01652176.2024.2424837.


1-L Transcription in Prion Diseases.

Nahalka J Int J Mol Sci. 2024; 25(18).

PMID: 39337449 PMC: 11431846. DOI: 10.3390/ijms25189961.


Prion diseases disrupt glutamate/glutamine metabolism in skeletal muscle.

Caredio D, Koderman M, Frontzek K, Sorce S, Nuvolone M, Bremer J PLoS Pathog. 2024; 20(9):e1012552.

PMID: 39259763 PMC: 11419395. DOI: 10.1371/journal.ppat.1012552.


Proliferative arrest induces neuronal differentiation and innate immune responses in normal and Creutzfeldt-Jakob Disease agent (CJ) infected rat septal neurons.

Pagano N, Perez G, Garcia-Milian R, Manuelidis L bioRxiv. 2024; .

PMID: 39131355 PMC: 11312452. DOI: 10.1101/2024.07.26.605349.


References
1.
Lam L, Chin L, Halder R, Sagong B, Famenini S, Sayre J . Epigenetic changes in T-cell and monocyte signatures and production of neurotoxic cytokines in ALS patients. FASEB J. 2016; 30(10):3461-3473. PMC: 5024692. DOI: 10.1096/fj.201600259RR. View

2.
Maas S, Rich A . Changing genetic information through RNA editing. Bioessays. 2000; 22(9):790-802. DOI: 10.1002/1521-1878(200009)22:9<790::AID-BIES4>3.0.CO;2-0. View

3.
Hwang T, Park C, Leung A, Gao Y, Hyde T, Kleinman J . Dynamic regulation of RNA editing in human brain development and disease. Nat Neurosci. 2016; 19(8):1093-9. DOI: 10.1038/nn.4337. View

4.
Danecek P, Nellaker C, McIntyre R, Buendia-Buendia J, Bumpstead S, Ponting C . High levels of RNA-editing site conservation amongst 15 laboratory mouse strains. Genome Biol. 2012; 13(4):26. PMC: 3446300. DOI: 10.1186/gb-2012-13-4-r26. View

5.
Zhu C, Herrmann U, Li B, Abakumova I, Moos R, Schwarz P . Triggering receptor expressed on myeloid cells-2 is involved in prion-induced microglial activation but does not contribute to prion pathogenesis in mouse brains. Neurobiol Aging. 2015; 36(5):1994-2003. DOI: 10.1016/j.neurobiolaging.2015.02.019. View